Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > CD8+ TiLs and T-cell exhaustion

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon May 26, 2024 4:01pm

419 Views

Post# 36058133

RE:RE:CD8+ TiLs and T-cell exhaustion

CD8+ T cells are the key defensive cells within TME. Here, CD8+ T cells form functional circuity with dendritic cells (DCs) and natural killer (NK) cells. There is a positive cross-talk between CD8+ T cells with DCs. To explain, interaction between CD40 on DCs with CD40L primes CD8+ T cells to convert into cytotoxic T lymphocytes (CTLs). CD70 signaling in DCs and the activity of CD70/CD27 axis is important for effector and memory differentiation of CD8+ T cells.

https://www.sciencedirect.com/science/article/pii/S0753332223006145